Lithuania

BMI View: Lithuania's drug market is expected to post a gradual recovery over the next five years, but with a short-term worsening economic environment, public and private consumption... 2012-03-15

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: We view Valeant's move to purchase Lithuanian company Sanitas favourably, particularly in the wake of its failed hostile bid for Cephalon earlier in 2011.The premium Valeant... 2011-05-25

BMI View: The economies of Lithuania, Estonia and Latvia were among the worst hit in Europe during the global economic crisis of 2007-2010 and the region's drug markets have not been... 2011-03-08

BMI View: The attractiveness of Central and Eastern Europe (CEE) to multinational pharmaceutical companies has increased. The region scored 51.6 out of 100 in BMI's Pharmaceutical &... 2011-01-13

BMI View: The economies of Lithuania, Estonia and Latvia were among the worst hit in Europe during the global economic crisis of 2007-2010 and the region's drug markets have not been... 2010-12-16

BMI View: Lithuania is one of our least favourite Central and Eastern European (CEE) pharmaceutical markets. A weak economic environment, high unemployment and the prospect of a relatively... 2010-11-26